

**Notice of Allowability**

Application No.

10/063,554

Examiner

Daniel Kolker

Applicant(s)

GODDARD ET AL.

Art Unit

1649

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 9/11/06.
2. ☒ The allowed claim(s) is/are 1,2,3,5,4, renumbered as 1-5 respectively.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some\* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date \_\_\_\_\_.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO/SB/08),  
Paper No./Mail Date 9/11/06
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application
6. ☐ Interview Summary (PTO-413),  
Paper No./Mail Date \_\_\_\_\_
7. ☒ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other \_\_\_\_\_

DK  
11/22/06

RC Hayes

ROBERT C. HAYES, PH.D.  
PRIMARY EXAMINER

### DETAILED ACTION

1. The remarks and declarations filed 11 September 2006 have been entered. Claims 1 – 5 are pending and under examination.

2. Authorization for this examiner's amendment was given in a telephone interview with Anne Marie Kaiser on 20 November 2006.

3. The application has been amended as follows:

In the specification:

On p. 1, the title has been changed to - - PRO994 antibodies - - -

In the claims:

In claim 4, line 1, the phrase - - An antibody fragment - - - has been replaced with the phrase - - An isolated antibody fragment - - -

4. The following is an examiner's statement of reasons for allowance:

The claims of the instant invention are directed to antibodies which bind to SEQ ID NO:48. The specification provides several asserted utilities, including that the instant antibodies can be used to detect polypeptides differentially expressed in diseased tissue as compared to controls tissues of the same tissue type.

In previous office actions, the examiner had argued that the results of experiments using nucleic acid were not sufficiently predictive of the expression patterns of the encoded proteins and therefore did not allow one of skill in the art to know the use of the antibodies now claimed. In the remarks submitted 11 September 2006, applicant argues that the evidence of record support the assertion that protein expression levels are correlated with mRNA levels. Upon further consideration, the examiner agrees with applicant's reasoning, when the assay used to measure such mRNA levels is the RT-PCR assay that uses tissue-matched control samples, described on p. 140 of the specification. Therefore one of skill in the art would be able to use the antibodies now claimed to distinguish normal stomach from stomach tumor or normal rectum from rectum tumor, as asserted by applicant.

5. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the

Art Unit: 1649

issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

**Conclusion**

6. Claims 1 – 5 are allowed.
7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Daniel Kolker whose telephone number is (571) 272-3181. The examiner can normally be reached on Mon - Fri 8:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on (571) 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Daniel E. Kolker, Ph.D.  
November 22, 2006



ROBERT C. HAYES, PH.D.  
PRIMARY EXAMINER